SciGen to develop intranasal Hep B vaccine with NasVax

Sydney, Dec 10, 2007 (RWE via COMTEX) -- SCIGF | charts | news | PowerRating -- (RWE Australian Business News) SciGen Ltd (ASX:SIE) is to jointly develop and commercialise a prophylactic intranasal Hepatitis B vaccine with NasVax Ltd.

The product subject of the collaboration is under development, and will combine antigens for immunisation against Hepatitis B produced by SciGen with Nasvax unique adjuvant technology, and it will be directed towards intranasal delivery.

Moreover, SciGen was granted an option, exercisable during the 12 months after execution of the agreement, to obtain a non-exclusive licence to use Nasvax technology to develop an intramuscular prophylactic Hepatitis B vaccine under conditions to be mutually determined in the future.

According to Mr Saul Mashaal, chairman and CEO of SciGen, this agreement provides new opportunities in respect to the development of a new delivery for the Hepatitis B vaccine, especially in newborn and children, by combining the unique technologies of both companies to address demand for improved efficiency, reduction of the amount of repetitions necessary for vaccination and intranasal immunisation.

The world market for Hepatitis vaccines is presently estimated at about $US1.3bn.

rweabn.com.au

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index